FDA Compliance for Peptide Therapy and BPC 157 Holt Law FDA Issues Flurry of Warning Letters to Companies Making Unapproved Claims about CBD and Delta 8 Products Buchanan Ingersoll & Rooney PC FDA considers adding a dozen peptides to its bulk drug compounding list RAPS On August 15 2025, the U.S. Food & Drug Administration (FDA) issued a Warning Letter to Platinum Biologics LLC for marketing umbilicalcordderived products including exosome products (NanoEx & Nano Xsomes) without approval. FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures FDA Warning Letters Sent to Pet Product Companies NASC LIVE